Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's bosutinib misses endpoint in Phase III trial vs Gleevec, but still "important option"

This article was originally published in Scrip

Executive Summary

Pfizer's second-generation, investigational BCR-ABL inhibitor bosutinib has missed its primary endpoint in its first Phase III trial, BELA, pitting it against Novartis's Gleevec (imatinib) in newly diagnosed, chronic phase chronic myeloid leukaemia (CML). The study was presented at the American Society of Hematology (ASH) meeting in Orlando, Florida. The data, and the fact that Gleevec is due to come off patent in 2014, may consign the Pfizer drug to a second-line treatment for CML.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts